Company: TAK
Filing Date: 2025-10-30
Form Type: 6-K
Source: 0001395064-25-000152
Chunk: 26

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-10-30
Form: 6-K
Chunk 26
---
-related assumptions is expected to be immaterial.

• Assume global VYVANSE/ELVANSE sales of JPY 227.0 billion, a year-on-year decline of JPY 123.6 billion (35% decline at CER).

<div align='center'>13</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Six-month

Period Ended September 30, 2025 (Consolidated)

#### Forward looking statements
All forecasts in this document are based on information currently available to management, and do not represent a promise or guarantee to achieve these forecasts. Various uncertain factors could cause actual results to differ, such as changes in the business environment and fluctuations in foreign exchange rates. Should any significant event occur which requires the forecast to be revised, the Company will disclose it in a timely manner.

(5) Interim Dividend for Fiscal 2025

Takeda maintains its annual dividend projection of JPY 200 per share.

For the six-month period ended September 30, 2025, Takeda's Board of Directors approved the payment of an interim dividend of JPY 100 per share. The dividend will be paid from December 1, 2025.

<div align='center'>14</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Six-month

Period Ended September 30, 2025 (Consolidated)

2. Condensed Interim Consolidated Financial Statements [IFRS] and Major Notes

(1) Condensed Interim Consolidated Statements of Profit or Loss

|                                                                                  |     | JPY (millions, except per share data) 
 Six-month Period Ended September 30,  |      2024 |     |     |      2025 |
|:---------------------------------------------------------------------------------|:----|:--------------------------------------|----------:|:----|:----|----------:|
| Revenue                                                                          |     |                                       | 2,384,028 |     |     | 2,219,481 |
| Cost of sales                                                                    |     |                                       |  -781,265 |     |     |  -764,736 |
| Selling, general and administrative expenses                                     |     |                                       |  -538,312 |     |     |  -509,436 |
| Research and development expenses                                                |     |                                       |  -344,027 |     |     |  -305